Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial

被引:6
作者
Hu, Huabin [1 ,2 ,3 ]
Zhang, Jianwei [1 ,2 ,3 ]
Li, Yunfeng [4 ]
Wang, Xiaozhong [5 ]
Wang, Ziqiang [6 ]
Wang, Hui [2 ,3 ,7 ]
Kang, Liang [2 ,3 ,7 ]
Liu, Ping [4 ]
Lan, Ping [2 ,3 ,7 ]
Wu, Xiaojian [2 ,3 ,7 ]
Zhen, Yunhuan [8 ]
Pei, Haiping [9 ]
Huang, Zhongcheng [10 ]
Zhang, Hao [11 ]
Chen, Wenbin [12 ]
Zeng, Yongming [13 ]
Lai, Jiajun [14 ]
Wei, Hongbo [15 ]
Huang, Xuefeng [16 ]
Chen, Jiansi [17 ]
Chen, Jigui [18 ]
Tao, Kaixiong [19 ]
Xu, Qingwen [20 ]
Peng, Xiang [21 ]
Liang, Junlin [22 ]
Cai, Guanfu [23 ]
Ding, Kefeng [24 ]
Ding, Zhijie [25 ]
Hu, Ming [26 ]
Zhang, Wei [27 ]
Tang, Bo [28 ]
Hong, Chuyuan [29 ]
Cao, Jie [30 ]
Huang, Zonghai [31 ]
Cao, Wuteng [32 ]
Li, Fangqian [32 ]
Wang, Xinhua [32 ]
Wang, Chao [33 ]
Huang, Yan [33 ]
Zhao, Yandong [33 ]
Cai, Yue [1 ,2 ,3 ]
Ling, Jiayu [1 ,2 ,3 ]
Xie, Xiaoyu [1 ,2 ,3 ]
Wu, Zehua [1 ,2 ,3 ]
Shi, Lishuo [34 ]
Ling, Li [35 ,36 ]
Liu, Hao [37 ]
Wang, Jianping [2 ,3 ,7 ]
Huang, Meijin [2 ,3 ,7 ]
Deng, Yanhong [1 ,2 ,3 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Peoples R China
[2] Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 6, Biomed Innovat Ctr, Guangzhou, Peoples R China
[4] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Dept Colorectal Surg, Kunming, Peoples R China
[5] Shantou Cent Hosp, Dept Gastrointestinal Surg, Shantou, Peoples R China
[6] Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg,Sch Med, Chengdu, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Gen Surg, Guangzhou, Peoples R China
[8] Guizhou Med Univ, Affiliated Hosp, Dept Colorectal Surg, Guiyang, Peoples R China
[9] Cent South Univ, Xiangya Hosp, Dept Gen Surg, Changsha, Peoples R China
[10] Hunan Prov Peoples Hosp, Dept Gen Surg, Changsha, Peoples R China
[11] Dongguan Kanghua Hosp, Dept Gen Surg, Dongguan, Peoples R China
[12] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Colorectal Surg, Hangzhou, Peoples R China
[13] Shantou Univ, Affiliated Hosp 1, Med Coll, Dept Gastrointestinal Surg, Shantou, Peoples R China
[14] Yuebei Peoples Hosp, Dept Gastrointestinal Surg, Shaoguan, Peoples R China
[15] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Gastrointestinal Surg, Guangzhou, Peoples R China
[16] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Colorectal Surg, Schoolof Med, Hangzhou, Peoples R China
[17] Guangxi Med Univ, Canc Hosp, Dept Gastrointestinal Surg, Nanning, Peoples R China
[18] Eighth Hosp Wuhan, Dept Surg, Wuhan, Peoples R China
[19] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan, Peoples R China
[20] Guangdong Med Univ, Affiliated Hosp, Dept Gastrointestinal Surg, Zhanjiang, Peoples R China
[21] First Peoples Hosp Foshan, Dept Gastrointestinal Surg, Foshan, Peoples R China
[22] Guangxi Med Univ, Affiliated Hosp 1, Dept Coloproctol Surg, Nanning, Peoples R China
[23] Guangdong Prov Peoples Hosp, Dept Gastrointestinal Surg, Guangzhou, Peoples R China
[24] Zhejiang Univ, Affiliated Hosp 2, Canc Ctr, Peoples Dept Colorectal Surg & Oncol,Sch Med, Hangzhou, Peoples R China
[25] Xiamen Univ, Zhongshan Hosp, Dept Gastrointestinal Surg, Xiamen, Peoples R China
[26] Guangzhou Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Guangzhou, Peoples R China
[27] Naval Med Univ, Affiliated Hosp 1, Dept Colorectal Surg, Shanghai, Peoples R China
[28] Army Med Univ, Hosp Affiliated 1, Dept Gen Surg, Chongqing, Peoples R China
[29] Guangzhou Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Guangzhou, Peoples R China
[30] Guangzhou First Peoples Hosp, Dept Gen Surg, Guangzhou, Peoples R China
[31] Southern Med Univ, Zhujiang Hosp, Dept Gen Surg, Guangzhou, Peoples R China
[32] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Radiol, Guangzhou, Peoples R China
[33] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Pathol, Guangzhou, Peoples R China
[34] Sun Yat Sen Univ, Affiliated Hosp 6, Clin Res Ctr, Guangzhou, Peoples R China
[35] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat, Guangzhou, Peoples R China
[36] Sun Yat Sen Univ, Ctr Migrant Hlth Policy, Guangzhou, Peoples R China
[37] Rutgers Canc Inst New Jersey, Rutgers Sch Publ Hlth, Dept Biostat & Epidemiol, Biostat Shared Resource, Brunswick, NJ USA
关键词
ADJUVANT TREATMENT; COMPUTED-TOMOGRAPHY; PREOPERATIVE CHEMOTHERAPY; OPEN-LABEL; FLUOROURACIL; LEUCOVORIN; BEVACIZUMAB; IRINOTECAN; CARCINOMA; CETUXIMAB;
D O I
10.1200/JCO.23.01889
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEThe role of neoadjuvant chemotherapy (NAC) in colon cancer remains unclear. This trial investigated whether 3 months of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or capecitabine and oxaliplatin (CAPOX) as NAC could improve outcomes in patients with locally advanced colon cancer versus upfront surgery.PATIENTS AND METHODSOPTICAL was a randomized, phase III trial in patients with clinically staged locally advanced colon cancer (T3 with extramural spread into the mesocolic fat >= 5 mm or T4). Patients were randomly assigned 1:1 to receive six preoperative cycles of mFOLFOX6 or four cycles of CAPOX, followed by surgery and adjuvant chemotherapy (NAC group), or immediate surgery and the physician's choice of adjuvant chemotherapy (upfront surgery group). The primary end point was 3-year disease-free survival (DFS) assessed in the modified intention-to-treat (mITT) population.RESULTSBetween January 2016 and April 2021, of the 752 patients enrolled, 744 patients were included in the mITT analysis (371 in the NAC group; 373 in the upfront surgery group). At a median follow-up of 48.0 months (IQR, 46.0-50.1), 3-year DFS rates were 82.1% in the NAC group and 77.5% in the upfront surgery group (stratified hazard ratio [HR], 0.74 [95% CI, 0.54 to 1.03]). The R0 resection was achieved in 98% of patients who underwent surgery in both groups. Compared with upfront surgery, NAC resulted in a 7% pathologic complete response rate (pCR), significantly lower rates of advanced tumor staging (pT3-4: 77% v 94%), lymph node metastasis (pN1-2: 31% v 46%), and potentially improved overall survival (stratified HR, 0.44 [95% CI, 0.25 to 0.77]).CONCLUSIONNAC with mFOLFOX6 or CAPOX did not show a significant DFS benefit. However, this neoadjuvant approach was safe, resulted in substantial pathologic downstaging, and appears to be a viable therapeutic option for locally advanced colon cancer.
引用
收藏
页码:2978 / 2988
页数:29
相关论文
共 45 条
  • [41] Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
    Tie, Jeanne
    Cohen, Joshua D.
    Wang, Yuxuan
    Christie, Michael
    Simons, Koen
    Lee, Margaret
    Wong, Rachel
    Kosmider, Suzanne
    Ananda, Sumitra
    McKendrick, Joseph
    Lee, Belinda
    Cho, Jin Hee
    Faragher, Ian
    Jones, Ian T.
    Ptak, Janine
    Schaeffer, Mary J.
    Silliman, Natalie
    Dobbyn, Lisa
    Li, Lu
    Tomasetti, Cristian
    Papadopoulos, Nicholas
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Gibbs, Peter
    [J]. JAMA ONCOLOGY, 2019, 5 (12) : 1710 - 1717
  • [42] Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
    Tie, Jeanne
    Wang, Yuxuan
    Tomasetti, Cristian
    Li, Lu
    Springer, Simeon
    Kinde, Isaac
    Silliman, Natalie
    Tacey, Mark
    Wong, Hui-Li
    Christie, Michael
    Kosmider, Suzanne
    Skinner, Iain
    Wong, Rachel
    Steel, Malcolm
    Tran, Ben
    Desai, Jayesh
    Jones, Ian
    Haydon, Andrew
    Hayes, Theresa
    Price, Tim J.
    Strausberg, Robert L.
    Diaz, Luis A., Jr.
    Papadopoulos, Nickolas
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Gibbs, Peter
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (346)
  • [43] Comparison of Tumor Regression Grade Systems for Locally Advanced Rectal Cancer After Multimodality Treatment
    Trakarnsanga, Atthaphorn
    Goenen, Mithat
    Shia, Jinru
    Nash, Garrett M.
    Temple, Larissa K.
    Guillem, Jose G.
    Paty, Philip B.
    Goodman, Karyn A.
    Wu, Abraham
    Gollub, Marc
    Segal, Neil
    Saltz, Leonard
    Garcia-Aguilar, Julio
    Weiser, Martin R.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (10):
  • [44] Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
    Van Cutsem, Eric
    Labianca, Roberto
    Bodoky, Gyoery
    Barone, Carlo
    Aranda, Enrique
    Nordlinger, Bernard
    Topham, Claire
    Tabernero, Josep
    Andre, Thierry
    Sobrero, Alberto F.
    Mini, Enrico
    Greil, Richard
    Di Costanzo, Francesco
    Collette, Laurence
    Cisar, Laura
    Zhang, Xiaoxi
    Khayat, David
    Bokemeyer, Carsten
    Roth, Arnaud D.
    Cunningham, David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3117 - 3125
  • [45] The Perioperative Period is an Underutilized Window of Therapeutic Opportunity in Patients With Colorectal Cancer
    van der Bij, Gerben J.
    Oosterling, Steven J.
    Beelen, Robert H. J.
    Meijer, Sybren
    Coffey, John C.
    van Egmond, Marjolein
    [J]. ANNALS OF SURGERY, 2009, 249 (05) : 727 - 734